Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model

Journal of Pediatric Surgery

Volumn 38, Issue 7, 2003, Pages 1075-1079

  Soto III, Leland J ^a   Sorenson, Brent S ^a   Kim, Adam S ^a   Feltis, Brad A ^a   Leonard, Arnold S ^a   Saltzman, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Metastases; Prevention; Salmonella

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; LIVER CANCER; LIVER METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0037999939     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(03)00196-9     Document Type: Article

References (14)

1. American Cancer Society Inc: Cancer Facts and Figures 2001. Surveillance Research, 2001
2. Saltzman DA, Heise CP, Hasz DE, et al: Attenuated Salmonella typhimurium containing interleukin-2 decreases MCA-38 metastases: A novel anti-tumor agent. Cancer Biother Radiopharm 11:145-153, 1996
3. Saltzman DA, Katsanin E, Heise CP, et al: Patterns of hepatic and splenic colonization by attenuated Salmonella typhimurium containing the human gene for IL-2. Cancer Biother Radiopharm 12:37-45, 1997
4. Curtiss R III, Kelly SM: Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 55:3035-3043, 1987
5. Nakayama K, Kelly SM, Curtiss R IIIConstruction of an ASD+ expression cloning vectorStable maintenance and high-level expression of cloned genes in a Salmonella vaccine strain. Biotechnology 6:693-697, 1988
6. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Second Edition. Cold Spring Harbor Laboratory Press, 1989
7. Kintzel PE, Calis KA: Recombinant Interleukin-2: A biological response modifier. Clin Pharm 10:110-128, 1991
8. Marincola FM: Interleukin-2, Biologic Therapy of Cancer Updates 4:1-16, 1994
9. Whittington R, Faulds D: Interleukin-2: A review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs 46:446-514, 1993
10. Lafreniere R, Rosenberg S: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45:3755-3741, 1985
11. Figlin RA, Thompson JA, Bukowski RM, et alMulticenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521-2529, 1999
12. Rosenberg S, Lotze M, Muul L, et al: A progress on the treatment of 157 patients with advanced cancer using lymphikine-activated killer cells and interleukin-2 of high dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
13. Saltzman DA, Katsanis E, Heise CP, et al: Anti-tumor mechanisms of attenuated Salmonella typhimurium containing the gene for human IL-2: A novel anti-tumor agent? J Pediatr Surg 32:301-306, 1997
14. Pawalek JM, Low KB, Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537-4544, 1997